Indications
Montaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes Mellitus.
Limitations of Use
- It has not been studied in patients with a history of pancreatitis.
- It is not indicated for patients with Type 1 Diabetes Mellitus.
Pharmacology
Tirzepatide is a dual GIP receptor and GLP-1 receptor agonist.
It:
- Enhances glucose-dependent insulin secretion.
- Reduces glucagon levels.
- Improves glycemic control.
- Has prolonged activity through albumin binding.
- Increases both first- and second-phase insulin secretion.
Dosage & Administration
Route of Administration
Administer by subcutaneous injection.
Dosing Instructions
- Starting dose: 2.5 mg once weekly.
- After 4 weeks: Increase to 5 mg once weekly.
- If additional glycemic control is required, increase by 2.5 mg increments after at least 4 weeks on the current dose.
- Maximum dose: 15 mg once weekly.
Missed Dose
- Administer within 4 days (96 hours) after a missed dose.
- If more than 4 days have passed, skip the missed dose.
- Resume the regular weekly schedule.
Changing the Dosing Day
The weekly administration day may be changed if there are at least 72 hours between two doses.
Injection Sites
Rotate injection sites with each dose.
Preparation and Storage
- Do not freeze.
- Do not use if frozen.
- Protect from light.
- Inspect visually before administration.
- Do not use if discoloration or particles are present.
- Do not use if the prefilled syringe has been dropped.
- Do not dilute or mix with other drug solutions.
Drug Interactions
Insulin or Sulfonylureas
- Increased risk of hypoglycemia.
- Dose adjustment may be required.
Oral Medications
- Delayed gastric emptying may affect the absorption of orally administered medicines.
Oral Hormonal Contraceptives
- Switch to a non-oral contraceptive method or add a barrier method for 4 weeks after initiation and after each dose escalation.
Contraindications
Montaro is contraindicated in:
- Patients with hypersensitivity to Tirzepatide or any component of the formulation.
- Patients with a personal or family history of Medullary Thyroid Carcinoma (MTC).
- Patients with Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2).
Side Effects
Common adverse effects include:
- Nausea
- Diarrhoea
- Decreased appetite
- Vomiting
- Constipation
- Dyspepsia
- Abdominal pain
Pregnancy & Lactation
Pregnancy
Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation
Consider the benefits of breastfeeding and the mother's clinical need for Tirzepatide when making treatment decisions.
Precautions & Warnings
- Counsel patients regarding the risk of Medullary Thyroid Carcinoma (MTC).
- Monitor for signs and symptoms of pancreatitis.
- Reduce insulin or sulfonylurea dose if necessary to minimise hypoglycaemia.
- Discontinue immediately if hypersensitivity reactions occur.
- Monitor renal function in patients with renal impairment.
- Monitor patients with diabetic retinopathy for disease progression.
- Investigate suspected cholelithiasis appropriately.
Use in Special Populations
Children and Adolescents
Safety and effectiveness have not been established in patients under 18 years of age.
Overdose
Symptoms
Overdose may increase the severity of adverse reactions.
Management
Provide appropriate supportive treatment based on clinical symptoms. Due to the approximately 5-day half-life of Tirzepatide, prolonged observation may be required.